Data completeness
1/8 — Limited
PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins.
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCORTEN (desoxycorticosterone pivalate/DOCP) is a long-acting mineralocorticoid ester administered intramuscularly for treatment of hypoadrenocorticism in animals. It acts by controlling protein synthesis through steroid-receptor-mediated genetic transcription, primarily increasing renal sodium reabsorption and potassium excretion to restore electrolyte balance and extracellular fluid volume. The drug prevents life-threatening hypotensive shock and pre-renal azotemia in hypoadrenocorticoid patients by expanding blood volume and improving cardiac output.
Pre-Launch
Pre-launch stage indicates active development and commercialization planning; team building and go-to-market strategy are active priorities.
Mechanism of Action
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.